Acrivon Therapeutics, Inc.
ACRV
$2.05
-$0.06-2.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.17% | -10.48% | -4.30% | 2.53% | 5.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.98% | -11.63% | -5.70% | 4.28% | 23.74% |
| Operating Income | 16.98% | 11.63% | 5.70% | -4.28% | -23.74% |
| Income Before Tax | 13.65% | 7.74% | 3.29% | -6.20% | -24.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.65% | 7.74% | 3.29% | -6.20% | -24.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.65% | 7.74% | 3.29% | -6.20% | -24.57% |
| EBIT | 16.98% | 11.63% | 5.70% | -4.28% | -23.74% |
| EBITDA | 17.52% | 12.13% | 6.16% | -3.80% | -23.35% |
| EPS Basic | 16.05% | 9.80% | 16.94% | 21.16% | 18.86% |
| Normalized Basic EPS | 19.11% | 13.17% | 19.74% | 18.43% | 16.21% |
| EPS Diluted | 16.05% | 9.80% | 16.94% | 21.16% | 18.86% |
| Normalized Diluted EPS | 19.11% | 13.17% | 19.74% | 18.43% | 16.21% |
| Average Basic Shares Outstanding | 3.02% | 2.37% | 14.04% | 28.91% | 48.50% |
| Average Diluted Shares Outstanding | 3.02% | 2.37% | 14.04% | 28.91% | 48.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |